Bad LV and severe MR: How to proceed and how to predict LV improvement? Jan Vontobel, MD Heart Failure/Transplant St Paul‘s Hospital, Vancouver Canada
Bad LV and severe MR:
How to proceed and how to
predict LV improvement?
Jan Vontobel, MD
Heart Failure/Transplant
St Paul‘s Hospital, Vancouver
Canada
Conflict of interest
Travel Grant by St. Jude Medical
outline
Different Treatment options
Unresolved Questions
Impact of MR on prognosis
Etiologies of MR
Prevalence of valvular heart disease
Mitral Valve Anatomy
Mitral valve anatomy
Prevalence of valvular heart disease
V. Nkomo. Lancet 2006;368:1005-11
Etiology of MR
Mechanism:Carpentier II
(Exessive leafletmotion or prolaps)
Mechanism:Carpentier I + III
(anular dilatation andrestrictive leaflet
motion)
Echo criteria of severe MR
Vahanian. Eur Hear J 2012;33:2451-2496
Survival Probability in CHF
according to the degree of MR
B. Trichon. Am J Car 2003;91:538-543
Survival free of heart failure
according to the degree of MR
F. Bursi. Circ. 2005;111:295-301
35% free of
HF
84%
74%
Medical Therapy of Mitral Regurgitation
H. Levine. J Am Coll Cardiol. 1996;28:1083-91
Volume
Pre
ssu
re
∆V
∆P
EF 50% EF 30%
Medical Therapy of FMR
H. Levine. J Am Coll Cardiol. 1996;28:1083-91
Medical Therapy of FMR
H. Levine. J Am Coll Cardiol. 1996;28:1083-91
Medical Therapy of FMR
B. Lowes. Am J Cardiol. 1999;83:1201-1205
N. Bellenger, Heart 2004;90:760-765
CRT in FMR
R. van Bommel. Circ. 2011;124:912-919
LVEF 23% ±7%
MR improvers
MR non-improvers
Surv
ival
Follow-up (months)
Guidelines in FMR
Indications for mitralValve surgery in chronicsecondaryMitral regurgitation
European Heart Failure Guidelines, 2016
Surgery in FMR
A.Ciarka, Am J Cariol. 2010;106:395-401
Preoperative predictors of secondary recurrent MR after undersized
annuloplasty:
LVEDD > 65mm
Post. Mitral leaflet angle > 45°
Distal anterior mitral leaflet angle > 25°
Systolic tenting area > 2.5cm2
Coaptation distance > 10mm
End-systolic interpapillary muscle distance > 20mm
Systolic spericity index > 0.7
Surgery in FMR
M. Acker, N Engl J Med. 2014; 370:23-32
Surgery in FMR
Severe MR
Moderate MR30%
20%
10%
2.3%
28.4%
4.2%
32.6%
repair Replacement at 12months
M. Acker, N Engl J Med. 2014; 370:23-32
Euro Heart Survey
M. Mirabel, Eur Heart J. 2007; 28:1358-1365
5001 patients with valvular heart disease included:
- 33.6% Mitral regurgitation
51.3% of symptomaticpatients with severe MR were
denied surgery
Mitra Clip anatomical Considerations
Wunderlich, Eur Heart J. CVI 2013
Current evidence for Mitra Clip use
M. Taramasso, Cardiovasc. Med. 2015; 18:333-339
FIRST-
IN-MAN
RCT’S
REGIS-
TRIES
META-
ANA-
LYSES
EVEREST IN=55
TRAMI n=1,064
Pilot Eur.SentinelN=628
ACCESS-Europe†n=567
EVEREST HRR†N=78
Vakil
N=2,980
REALISM† (ongoing) n>300
GRASP n>117 (ongoing)
MitraSwiss n>500
CE Mark (march 2008)
EVEREST II roll-inN=52
EVEREST II N=279
RESHAPE
COAPT
D’Ascenzo
N=875
Philip
N=3,198
Wan
N=349
Munkholm
N=878
MATTER-
HORN
MITRA-FRHIRIDE
**for degenerative MR with prohibitive surgical risk
† industry-sponsored registries
ǀ ǀ ǀ ǀ ǀ ǀ ǀ ǀ ǀ ǀ ǀ ǀ ǀ
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
https://en.wikipedia.org/wiki/File:Flag_of_Italy.svghttps://en.wikipedia.org/wiki/File:Flag_of_Italy.svghttp://www.google.ch/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0CAcQjRxqFQoTCI-Mz-zbk8YCFc4g2wodzvQAkg&url=http://commons.wikimedia.org/wiki/File:Flag_of_Switzerland_(Pantone).svg&ei=zdN_Vc_xA87B7AbO6YOQCQ&bvm=bv.96041959,d.d24&psig=AFQjCNGEjGRE9ZqZq-OMgz4lYNfOxxn-Eg&ust=1434527051379280http://www.google.ch/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0CAcQjRxqFQoTCI-Mz-zbk8YCFc4g2wodzvQAkg&url=http://commons.wikimedia.org/wiki/File:Flag_of_Switzerland_(Pantone).svg&ei=zdN_Vc_xA87B7AbO6YOQCQ&bvm=bv.96041959,d.d24&psig=AFQjCNGEjGRE9ZqZq-OMgz4lYNfOxxn-Eg&ust=1434527051379280http://www.google.ch/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0CAMQjRxqFQoTCMjc7rvek8YCFQGWLAod8e0PcQ&url=http://en.wikipedia.org/wiki/Flag_of_Germany&ei=jNZ_VcjmB4GssgHx27-IBw&bvm=bv.96041959,d.bGg&psig=AFQjCNELpbaoVerdeFWhg6oTdW3GJY7WLw&ust=1434527756167038http://www.google.ch/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0CAMQjRxqFQoTCMjc7rvek8YCFQGWLAod8e0PcQ&url=http://en.wikipedia.org/wiki/Flag_of_Germany&ei=jNZ_VcjmB4GssgHx27-IBw&bvm=bv.96041959,d.bGg&psig=AFQjCNELpbaoVerdeFWhg6oTdW3GJY7WLw&ust=1434527756167038http://www.google.ch/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0CAMQjRxqFQoTCMjc7rvek8YCFQGWLAod8e0PcQ&url=http://en.wikipedia.org/wiki/Flag_of_Germany&ei=jNZ_VcjmB4GssgHx27-IBw&bvm=bv.96041959,d.bGg&psig=AFQjCNELpbaoVerdeFWhg6oTdW3GJY7WLw&ust=1434527756167038http://www.google.ch/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0CAMQjRxqFQoTCMjc7rvek8YCFQGWLAod8e0PcQ&url=http://en.wikipedia.org/wiki/Flag_of_Germany&ei=jNZ_VcjmB4GssgHx27-IBw&bvm=bv.96041959,d.bGg&psig=AFQjCNELpbaoVerdeFWhg6oTdW3GJY7WLw&ust=1434527756167038http://www.google.ch/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0CAcQjRxqFQoTCKSqhbGPlMYCFWWPcgodzuIACQ&url=http://en.wikipedia.org/?title=Flag_of_France&ei=1gmAVaTnLuWeygPOxYNI&bvm=bv.96041959,d.bGg&psig=AFQjCNFhnCT9kjjS7R-rd6LIyj33wBrL3g&ust=1434540881426074http://www.google.ch/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0CAcQjRxqFQoTCKSqhbGPlMYCFWWPcgodzuIACQ&url=http://en.wikipedia.org/?title=Flag_of_France&ei=1gmAVaTnLuWeygPOxYNI&bvm=bv.96041959,d.bGg&psig=AFQjCNFhnCT9kjjS7R-rd6LIyj33wBrL3g&ust=1434540881426074
Reduction in MR and LV/LA Remodeling
P. Grayburn, Circ. 2013; 128:1667-1674
Usefulness of MitraClip in FMR
F. D’Ascenzo, Am J Cardiol. 2015; 116:325-331
Unanswered Questions
Does MitraClip compared to Optimal Medical Treatment improve the prognosis of thepatients?
Is the Mitral Regurgitation itself independently and prognostically causative relevant or isit just a Bystander?
Randomized Controlled Trials are needed - COAP Trial
Predictive parameters of outcome in medical as well as interventional treatmentsTime of referral?
At present what to do in FMR
Optimal Medical Therapy
CRT where indicated
Surgery if CABG and LVEF>30%; LVEF 1year
M. Taramasso, Cardiovasc. Med. 2015; 18:333-339
Guidelines in FMR
European Guidelines on the management of valvular heart disease, 2012
Indications for mitralValve surgery in chronicsecondaryMitral regurgitation
European Guidelines on myocardial revascularization, 2014
European Heart Failure Guidelines, 2016
EVEREST II HRR or REALISM HR
D. Glower, JACC. 2014; 64:172-81
Medical Therapy of FMR
H. Okura. Heart. 2016;10
EF≥50% EF≤50%